<DOC>
	<DOCNO>NCT02813720</DOCNO>
	<brief_summary>Nearly 30 % patient cutaneous psoriasis ( PsO ) develop psoriatic arthritis ( PsA ) . Among patient 20 % severe destructive arthritis . The risk develop PsA significantly high patient nail involvement ( OR = 2.24 ; 95 % CI [ 1.26-3.98 ] ) . The risk particularly high peripheral form PsA onycholysis ( OR=2.80 ; 95 % CI [ 1.34-5.85 ] ) . Thus investigator want test hypothesis onycholysis , patient without PsA , potential clinical marker subclinical distal enthesopathy , extension , bone micro-structural alteration . Patients Methods The investigator recruit 4 group subject : 1 . Patients peripheral PsA , 2 . Patients psoriatic nail onycholysis , 3 . Patients PsO 4 . Healthy match control subject . The investigator assess presence enthesopathy ultrasonography bone structural damage ( HR-pQCT ) subject baseline 4 year .</brief_summary>
	<brief_title>Distal Erosions Nail Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>adult 18 year 65 year gender cover French National Insurance subject enter one 4 group . Treatment biological agent exclusion criterion PsO , onycholysis control patient . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Erosions</keyword>
	<keyword>Onycholysis</keyword>
	<keyword>HR-pQCT</keyword>
	<keyword>Psoriatic arthritis</keyword>
</DOC>